(1S,2S)-N1-Methylcyclohexane-1,2-diamine | 942435-48-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (1S,2S)-N1-Methylcyclohexane-1,2-diamine
• 英文别名: (1S,2S)-2-N-methylcyclohexane-1,2-diamine
• CAS: 942435-48-5
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: UZFSSDLWBZWJRU-BQBZGAKWSA-N

物化性质

• 沸点：
  180.1±8.0 °C(Predicted)
• 密度：
  0.92±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1S,2S)-N1-Methylcyclohexane-1,2-diamine 、 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazole-4-carboxylic acid 在 fluoro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(methylamino)cyclohexyl)-1H-imidazole-4-carboxamide
  参考文献：
  名称：

  Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity

  摘要：

  Several imidazole-based cyclohexyl amides were identified as potent CB-1 antagonists, but they exhibited poor oral exposure in rodents. Incorporation of a hydroxyl moiety on the cyclohexyl ring provided a dramatic improvement in oral exposure, together with a ca. 10-fold decrease in potency. Further optimization provided the imidazole 2-hydroxy-cyclohexyl amide 45, which exhibited hCB-1 K-i = 3.7 nM and caused significant appetite suppression and robust, dose-dependent reduction of body weight gain in industry-standard rat models. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.011

文献信息

• [EN] IRE1α MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE IRE1α ET LEURS UTILISATIONS
  申请人：NIMBUS IASO INC

  公开号：WO2021158516A1

  公开（公告）日：2021-08-12

  The present invention provides compounds, compositions thereof, and methods of using the same for the modulation of IRE1α, and the treatment of IRE1α-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物调节IRE1α并治疗IRE1α介导的疾病的方法。
• Pyrimidine derivatives as ALK-5 inhibitors
  申请人：Novartis AG

  公开号：EP1878733A1

  公开（公告）日：2008-01-16

  Compounds of formula I in free or salt or solvate form, where T1, T2, K, Ra and Rb have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  公式I中的化合物以自由形式、盐或溶剂形式存在，其中T1、T2、K、Ra和Rb的含义如规范中所示，可用于治疗由ALK-5和/或ALK-4受体介导的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的过程。
• CONDENSED IMIDAZOLE DERIVATIVES
  申请人：Yoshikawa Seiji

  公开号：US20090018331A1

  公开（公告）日：2009-01-15

  The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T 1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents; X represents a C 1-6 alkyl group which may have one or more substituents, or such; Z 1 and Z 2 each independently represent a nitrogen atom or a group represented by the formula —CR 2 —; R 1 and R 2 independently represent a hydrogen atom, a C 1-6 alkyl group which may have one or more substituents, or a C 1-6 alkoxy group which may have one or more substituents, or such. These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.

  本发明涉及下式所示的化合物、盐或水合物： 其中， T1表示一个4-到12成员的杂环基团，在环中含有一个或两个氮原子，是单环或双环结构，可以有一个或多个取代基； X表示一个C1-6烷基基团，可以有一个或多个取代基； Z1和Z2各自独立地表示一个氮原子或由公式—CR2—表示的基团； R1和R2各自独立地表示氢原子、一个C1-6烷基基团，可以有一个或多个取代基，或一个C1-6烷氧基基团，可以有一个或多个取代基。 这些是具有出色的DPPIV抑制活性的新型化合物。
• Novel condensed imidazole derivative
  申请人：Nakahira Hiroyuki

  公开号：US20070105890A1

  公开（公告）日：2007-05-10

  Disclosed is a compound represented by the formula (1) below which has a high DPP-IV inhibitory activity and is improved in safety, toxicity and the like. Also disclosed is a prodrug of such a compound and pharmaceutically acceptable salts of them. (In the formula, R 1 represents a hydrogen atom, an optionally substituted alkyl group or the like; R 2 and R 3 independently represent a hydrogen atom, an optionally substituted alkyl group or the like; R 4 and R 5 independently represent a hydrogen atom, an optionally substituted alkyl group or the like: R 6 represents a hydrogen atom, an optionally substituted aryl group or the like; and —Y—NH 2 , represents a group represented by the following formula (A): (wherein m is 0, 1 or 2; and R 7 may not exist or one or two R 7 may exist and independently represent an optionally substituted alkyl group or the like) or the like.]

  公开了一种化合物，其表示为以下式（1），具有较高的DPP-IV抑制活性并且在安全性、毒性等方面得到改善。还公开了这种化合物的前药和它们的药学上可接受的盐。（在该式中，R1表示氢原子，可选择性取代的烷基或类似物; R2和R3独立地表示氢原子，可选择性取代的烷基或类似物; R4和R5独立地表示氢原子，可选择性取代的烷基或类似物：R6表示氢原子，可选择性取代的芳基或类似物; 而—Y—NH2表示由以下式（A）表示的基团：（其中m为0、1或2；而R7可能不存在或一个或两个R7可能存在且独立地表示可选择性取代的烷基或类似物）或类似物。）
• Unified and green oxidation of amides and aldehydes for the Hofmann and Curtius rearrangements
  作者：Liyan Song、Yufei Meng、Tongchao Zhao、Lifang Liu、Xiaohong Pan、Binbin Huang、Hongliang Yao、Ran Lin、Rongbiao Tong

  DOI：10.1039/d3gc04355j

  日期：——

  The Hofmann and Curtius rearrangements have been widely used in organic synthesis and developed for the industrial production (5–100 kg) of pharmaceutically relevant amines/amides. However, the existing use of a stoichiometric organic oxidant [(diacetoxyiodo)benzene or trichloroisocyanuric acid for the Hofmann rearrangement] for amides or an activating reagent (diphenylphosphoryl azide for the Curtius

  霍夫曼和库尔蒂斯重排已广泛应用于有机合成，并被开发用于医药相关胺/酰胺的工业生产（5-100 kg）。然而，现有的酰胺化学计量有机氧化剂[（二乙酰氧基碘）苯或三氯异氰脲酸用于霍夫曼重排]或羧酸活化剂（二苯基磷酰叠氮化物用于库尔蒂斯重排）对环境不友好且经济上缺乏吸引力。在此，我们报道了酰胺和醛与过酮和卤化物（和NaN 3）的首次绿色氧化，分别生成N-卤代酰胺和酰基叠氮化物，两者重排成常见的异氰酸酯中间体，随后产生稳定的氨基甲酸酯或脲。霍夫曼和库尔蒂斯重排）当被醇或胺捕获时。每次重新安排都有 30 多个示例，证明这种统一的绿色方法非常高效。重要的是，该方法产生无机无毒K 2 SO 4作为唯一的副产物，这比生产化学计量的、有毒的有机碘苯、氯异氰尿酸或二苯基磷酸的现有方法更有优势。值得注意的是，通过这种绿色氧化库尔蒂斯重排，可以从相应的醛有效合成三种尿素基药物和八种手性尿素催化剂。这种用于霍夫曼和